Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate) 通过阻断钙介导的凋亡通路和 Caspase-12的活化来阻止细胞凋亡。它可用于原发性胆汁性肝硬化、胰岛素抵抗、淀粉样变性、囊性纤维化、胆汁淤积和肌萎缩侧索硬化症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 108 | 现货 | ||
2 mg | ¥ 137 | 现货 | ||
5 mg | ¥ 198 | 现货 | ||
10 mg | ¥ 313 | 现货 | ||
25 mg | ¥ 619 | 现货 | ||
50 mg | ¥ 892 | 现货 | ||
100 mg | ¥ 1,320 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 245 | 现货 |
产品描述 | Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. |
体内活性 | At all infusion rates, taurohyodeoxycholic acid caused a greater (P < 0.001) secretion of biliary lecithin compared to the other bile salts. There were no significant differences in the biliary secretion of cholesterol and proteins. Electron microscopy showed the recruitment of vesicles and lamellar bodies around and within bile canaliculi. In conclusion, taurohyodeoxycholic promotes a biliary lecithin secretion greater than expected from physicochemical predictions, representing a novel secretory property with potential pharmacological relevance[1]. |
别名 | Sodium taurodeoxycholate monohydrate, Taurodeoxychloic Acid sodium hydrate, Taurohyodeoxycholic acid sodium salt, 牛磺猪去氧胆酸 |
分子量 | 540.71 |
分子式 | C26H47NNaO7S |
CAS No. | 110026-03-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (231.18 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8494 mL | 9.2471 mL | 18.4942 mL | 46.2355 mL |
5 mM | 0.3699 mL | 1.8494 mL | 3.6988 mL | 9.2471 mL | |
10 mM | 0.1849 mL | 0.9247 mL | 1.8494 mL | 4.6236 mL | |
20 mM | 0.0925 mL | 0.4624 mL | 0.9247 mL | 2.3118 mL | |
50 mM | 0.037 mL | 0.1849 mL | 0.3699 mL | 0.9247 mL | |
100 mM | 0.0185 mL | 0.0925 mL | 0.1849 mL | 0.4624 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Taurodeoxycholic acid sodium hydrate 110026-03-4 Apoptosis Proteases/Proteasome Caspase Taurodeoxycholic acid sodium Taurodeoxycholic acid sodium Hydrate Inhibitor Sodium taurodeoxycholate Taurohyodeoxycholic acid sodium Sodium taurodeoxycholate monohydrate Taurodeoxychloic Acid sodium hydrate Taurohyodeoxycholic acid sodium salt Taurodeoxychloic Acid sodium Hydrate 牛磺猪去氧胆酸 inhibit Sodium taurodeoxycholate Monohydrate inhibitor